VTRS
HealthcareViatris
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2018–2025(8yr)| Metric | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4B | $11.5B | $11.9B | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B | -3.0% |
| Gross Profit | $4.0B | $3.9B | $3.8B | $5.6B | $6.5B | $6.4B | $5.6B | $5.0B | -10.8% |
| Gross Margin | 35.0% | 33.9% | 31.8% | 31.2% | 40.0% | 41.7% | 38.2% | 35.1% | -3.1pp |
| Operating Income | $905.6M | $715.5M | -$210.8M | -$34.0M | $1.6B | $766.2M | $10.1M | -$2.7B | -26467.3% |
| Operating Margin | 7.9% | 6.2% | -1.8% | -0.2% | 9.9% | 5.0% | 0.1% | -18.6% | -18.7pp |
| Net Income | $352.5M | $16.8M | -$669.9M | -$1.3B | $2.1B | $54.7M | -$634.2M | -$3.5B | -454.2% |
| Net Margin | 3.1% | 0.1% | -5.6% | -7.1% | 12.8% | 0.4% | -4.3% | -24.6% | -20.3pp |
| Free Cash Flow | $2.1B | $1.6B | $988.8M | $2.6B | $2.5B | $2.4B | $2.0B | $1.9B | -2.0% |
| FCF Margin | 18.3% | 13.8% | 8.3% | 14.3% | 15.7% | 15.7% | 13.4% | 13.5% | +0.1pp |
| EPS (Diluted) | $0.68 | $0.03 | $-1.11 | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 | -466.0% |
1. THE BIG PICTURE
Viatris is currently executing a high-stakes transformation, attempting to move away from the low-margin "divide" of traditional generics toward a portfolio of "limited-competition complex and novel products" (10-K Item 1). While the most recent quarter showed a 5% revenue uptick, Viatris remains structurally unprofitable on a GAAPGAAPGenerally Accepted Accounting Principles — the standard U.S. accounting rules all public companies must follow basis and is burdened by $13.5 billion in net debt (8-K, XBRL). The success of this pivot depends entirely on whether its new product pipeline—including assets like selatogrel and cenerimod—can outpace the relentless price erosion mandated by governments in its key international markets.
2. WHERE THE RISKS HIT HARDEST
Viatris’s "one-of-a-kind" global supply chain, which it cites as a core competitive advantage, is currently a primary source of financial instability due to regulatory failures (10-K Item 1). The December 2024 FDA warning letter and import alert for the Indore, India facility directly undermine Viatris's "commercial reach" by restricting product distribution into the U.S. (10-K Item 1A). Furthermore, Viatris’s "portfolio breadth" is being hollowed out by external policy; the 10% net sales growth in Greater China is under constant threat from Volume-Based Procurement (VBP) bidding that has forced price cuts as high as 96% for certain molecules (8-K, 10-K Item 1A).
3. WHAT THE NUMBERS SAY TOGETHER
The financial data reveals a business struggling with efficiency despite its massive global scale. Viatris maintains the lowest gross margin in its peer group at 37.1%, a stark contrast to branded peers like Pfizer (74.4%) or Incyte (92.9%) (XBRL). While management points to "disciplined execution," the TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter revenue growth of -3.0% suggests that the base business was contracting for much of the year, even though the final quarter of 2025 saw a 5% increase (8-K, XBRL). This recent divergence was driven by European growth and new product launches finally offsetting North American competition and Japanese price regulations (8-K). With net debt standing at 6.5x annual free cash flow, Viatris has very little margin for error as it attempts to extract $650 million in cost savings through 2028 (8-K, CAPM analysis).
4. IS IT WORTH IT AT THIS PRICE?
At a forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations of 5.3x, Viatris is the cheapest stock in its peer group, trading at a nearly 50% discount to the peer median of 10.3x (Yahoo Finance). According to market-implied growth expectations, the current price assumes a long-term growth rate of just 0.5%; if Viatris were to achieve even modest GDP-pace growth of 2.5%, the justified multiple would rise to 15.7x (CAPM analysis). This deep discount is a direct result of Viatris's -21.5% net margin and the high execution risk associated with its restructuring (XBRL, 10-K Item 1A). For the current valuation to be "fair," Viatris must prove that its projected $450 million to $550 million in 2026 new product revenue is not immediately cannibalized by the "rapid sales declines" that occur when legacy products like Amitiza lose exclusivity (8-K, 10-K Item 1A).
5. WHAT WOULD CHANGE THIS VIEW?
- Constructive if the FDA lifts the import alert on the Indore facility, signaling a resolution to the quality compliance issues that currently restrict U.S. supply.
- Cautious if 2026 new product revenue falls below the $450 million guidance floor, suggesting the innovation pipeline is failing to offset generic erosion.
- Cautious if the planned 10% headcount reduction fails to improve the operating margin, which currently trails the peer group at -15.6% (XBRL, 10-K Item 1A).
6. BOTTOM LINE
Structural Advantage: A massive global distribution infrastructure reaching 165 countries that allows Viatris to bridge the gap between low-cost generics and complex branded therapies. Bottom Line: Viatris is a distressed value play whose bargain-basement valuation is a fair reflection of its high debt and the regulatory clouds hanging over its manufacturing base.
1. Top 5 Material Risks
- Pricing and Reimbursement Pressure: Viatris faces systemic pressure from government-imposed price controls, tender systems, and mandatory rebates. In China, the centralized Volume-Based Procurement (VBP) policy has led to price cuts as high as 96% for certain molecules, and Viatris expects these pressures to increase as the URP policy caps reimbursement at VBP tender levels.
- Manufacturing and Supply Chain Disruptions: Viatris relies on a limited number of internal and third-party manufacturing facilities. Regulatory actions, such as the December 2024 FDA warning letter and import alert for the Indore, India facility, have restricted the distribution of products into the U.S. and other regions, directly impacting financial condition and cash flows.
- Generic Competition and Loss of Exclusivity: Viatris faces vigorous competition from manufacturers of generic and biosimilar drugs. The loss of patent protection or market exclusivity—such as the expected loss for Amitiza® 24 μg in Japan in June 2026—typically results in rapid sales declines and margin erosion.
- Strategic Execution and Restructuring: The 2025 Enterprise-Wide Strategic Review (EWSR) involves significant restructuring, including headcount reductions of up to 10% and facility closures. There is no guarantee these activities will achieve intended cost savings or that they will not cause operational momentum loss or higher-than-anticipated expenses.
- Indebtedness and Financial Flexibility: Viatris carries significant indebtedness, which limits financial flexibility and requires a substantial portion of cash flow for debt service. Refinancing this debt could occur at significantly higher interest rates, further constraining the ability to fund R&DR&DResearch & Development — spending on creating new products or technologies, dividends, or share repurchases.
2. Company-Specific Risks
- Concentration of Revenue: A significant portion of net sales is derived from a limited group of products and customers. The top ten products represented 36% of net sales in 2025, while the top three customers accounted for 25% of consolidated total net sales, making Viatris highly sensitive to the loss of any single major contract or product volume.
- Divestiture Exposure: Viatris retains ongoing financial and operational exposure to divested businesses (such as the Biocon Biologics Transaction) through transition services, indemnification obligations, and supply arrangements, which can lead to stranded costs or litigation.
- Integration Challenges: The combination of independent businesses remains a complex, costly process. Failure to realize anticipated synergies from acquisitions or to successfully integrate IT, manufacturing, and logistics systems could result in material adverse effects on results of operations.
- Opioid Litigation Indemnification: Viatris is obligated to pay Pfizer 57% of losses incurred by Viatris arising from third-party actions related to the manufacture, distribution, or sale of opioid products by or on behalf of Viatris or its predecessors.
3. Regulatory/Legal Risks
- Anti-Corruption Compliance: Viatris is subject to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, and Chinese anti-corruption laws. Given that many hospitals in its operating jurisdictions are government-owned, employees and agents are frequently considered "foreign officials," increasing the risk of substantial fines and criminal penalties.
- Intellectual Property Litigation: Viatris faces frequent patent infringement litigation from branded pharmaceutical companies. "At-risk launches" of generic products expose Viatris to potential damages of up to three times the profits earned if the infringement is found to be willful.
- Data Privacy and Cybersecurity: Viatris is subject to evolving global data protection frameworks, including the EU’s GDPR and NIS2 Directive, and China’s Data Security Law. Non-compliance can result in fines up to 4% of total annual worldwide revenue or €20 million, whichever is higher.
- Environmental Regulation: Viatris faces increasing costs related to "extended producer responsibility" regulations in the EU, which may require Viatris to fund upgrades to public wastewater treatment plants to eliminate pharmaceutical micropollutants.
4. Financial Impact Map
- VBP Bidding/Pricing Pressure → Net Sales → Significant volume and price erosion in the Chinese market.
- Indore Facility Warning Letter → Net Sales / Cash Flows → Restricted ability to distribute products into the U.S. and other regions.
- Goodwill/Intangible Impairments → Net Income / Earnings Per Share → Significant charges, such as the $2.94 billion goodwill impairment in 2025, directly reduce earnings.
- Restructuring Activities → Operating Expenses → Costs associated with headcount reductions and facility closures may exceed anticipated savings.
- Indebtedness → Interest Expense / Cash Flow → High debt levels require significant cash allocation, limiting funds for R&DR&DResearch & Development — spending on creating new products or technologies and capital expenditures.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 8-K | Feb 2026 | — |
| 10-K | Feb 2026 | Dec 2025 |
| 10-Q | Nov 2025 | Sep 2025 |
| 14A | Oct 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Viatris Q4 Revenue $3.7B +5% YoY, Adjusted EPS $0.57, Shares Fell 5.2%
- ▸Q4 revenue $3.7B, up 5% YoY
- ▸Q4 adjusted EPS $0.57
- ▸Shares fell 5.2% following Q4 earnings announcement
- ▸Stock trading 19.9% below 52-week high of $16.47
- ▸Analyst consensus rating Moderate Buy with $15.55 mean price target
Viatris FY26 Revenue Guidance $14.45B–$14.95B, Maintains Annual Dividend of $0.48/Share
- ▸FY25 revenue $14.3B with net loss of $3.51B
- ▸FY26 revenue guidance range $14.45B–$14.95B
- ▸Maintains annual dividend of $0.48 per share
- ▸Long-term 2028 target: $14.5B revenue and $419.7M earnings
- ▸Strategy focuses on product launches, pipeline execution, and capital returns
Theravance Q4 EPS $0.06 misses $0.44 estimate; revenue $45.9M misses $60M target
- ▸Q4 adjusted EPS $0.06 vs $0.44 estimate
- ▸Q4 revenue $45.9M vs $60M estimate
- ▸Ampreloxetine Phase III CYPRESS study failed to meet primary endpoint
- ▸Company to wind down ampreloxetine development program
- ▸FY2025 revenue $107.4M, up 67% YoY
Viatris Targets 9-10% Adjusted EPS CAGR Through 2030 at Investor Day
- ▸Targeting 5-6% total revenue CAGR through 2030
- ▸Projecting 7-8% adjusted EBITDA CAGR through 2030
- ▸Targeting 9-10% adjusted EPS CAGR through 2030
- ▸Expecting over $3 billion in annual free cash flow by 2030
- ▸Over $11 billion in cash available for deployment through 2030
Theravance Biopharma Q4 results show record profitability, $75M in milestone payments, restructuring underway
- ▸Restructuring to generate $60M–$70M annualized cash flow starting Q3 2026
- ▸YUPELRI full-year net sales $266.6M, up 12% YoY
- ▸TRELEGY full-year net sales $3.9B, triggered $50M milestone payment
- ▸Projected Q1 2026 cash balance of $400M with zero debt
- ▸Achieved record non-GAAP profitability for second consecutive quarter
Theravance Biopharma initiates restructuring to save $60M-$70M annually; explores sale of company
- ▸Organizational restructuring to generate $60M–$70M annualized cash flow by Q3 2026
- ▸Strategic Review Committee actively evaluating sale of company to maximize shareholder value
- ▸YUPELRI full-year net sales $266.6M, up 12% YoY; triggered $25M milestone
- ▸TRELEGY full-year net sales $3.9B, up 12% YoY; triggered $50M milestone
- ▸Projected Q1 2026 cash balance of $400M with zero debt
Viatris Targets 9-10% Adjusted EPS CAGR Through 2030 at Investor Day
- ▸Projected 5-6% total revenue CAGR through 2030
- ▸Targeting 7-8% adjusted EBITDA CAGR through 2030
- ▸Expected 9-10% adjusted EPS CAGR through 2030
- ▸Forecasts over $3B in annual free cash flow by 2030
- ▸Over $11B in cash available for deployment through 2030
Viatris Q4 revenue $3.7B, Truist raises price target to $18 following results
- ▸Q4 revenue $3.7B, +1% YoY excluding Indore facility impact
- ▸FY2025 total revenue $14.3B
- ▸FY2025 free cash flow $2.2B excluding transaction costs
- ▸FY2026 forecast: 2% growth in adjusted EBITDA and total revenue
- ▸Projected $450M–$550M revenue from new product launches in 2026
Viatris Price Targets Raised by UBS to $20 and BofA to $12
- ▸UBS raised price target to $20 from $18, maintains Buy rating
- ▸BofA raised price target to $12 from $10, maintains Underperform rating
- ▸Company targeting $400 million in net cost reductions over three years
- ▸Approximately 50% of cost savings expected from lower cost of goods sold
- ▸Investor event scheduled for March 19 to outline long-term growth strategy